Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
381 stopped studies mapped to Malignant Kidney Neoplasm and descendants · 86% state a reason
Over the 381 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients… | Phase 2 | terminated | May 1, 2020 | University of California, San Francisco | Collaborating sponsor decision | Sponsor / business decision |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell… | Phase 1 / Phase 2 | terminated | Nov 15, 2021 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell… | Phase 2 | terminated | Jul 7, 2023 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT07117409 | Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure(RI-NIVO) | — | terminated | Aug 12, 2025 | Azienda USL Reggio Emilia - IRCCS | Healted Prematurely | Other (stated, no rule matched) |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 12, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | funding withdrawn | Funding |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain… | Phase 2 | withdrawn | Jun 10, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT06264479 | Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal…(PEAR-TREE2) | — | terminated | Feb 20, 2024 | Ourotech, Inc. | Lack of funding | Funding |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With… | — | withdrawn | Dec 30, 2020 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT02446860 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic…(ADAPTeR) | Phase 2 | terminated | May 18, 2015 | Royal Marsden NHS Foundation Trust | The study was unable to recruit the target number of patients (enrolled 15 instead of 19) and did… | Enrollment / accrual |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney… | Early Phase 1 | withdrawn | Feb 2, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by the IRB | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04267120 | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally… | Phase 2 | terminated | Feb 12, 2020 | Washington University School of Medicine | Slow enrollment with low accrual | Enrollment / accrual |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT06884683 | Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma(NivoMet) | Phase 2 | terminated | Mar 19, 2025 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | slow enrollment | Enrollment / accrual |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer… | Phase 2 | terminated | Aug 3, 2020 | Emory University | This study was terminated after interim analyses showed no benefits. | Efficacy / futility |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC…(PREPARE) | Phase 3 | terminated | Jan 9, 2017 | AIO-Studien-gGmbH | insufficient accrual rate | Enrollment / accrual |
| NCT05534789 | Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell… | — | terminated | Sep 10, 2022 | Pfizer | The trial prematurely terminated due to the inability to recruit the planned number of… | Safety / toxicity |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Jun 18, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT05119010 | A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in…(KETOREIN) | N/A | terminated | Nov 12, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Recruitment challenges: competition with another microbiome trial, patient refusal to join a… | Enrollment / accrual |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | Phase 2 | terminated | Feb 24, 2023 | ImaginAb, Inc. | Strategic decision | Sponsor / business decision |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03393936 | Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage… | Phase 1 / Phase 2 | terminated | Jan 9, 2018 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK… | Phase 2 | withdrawn | Oct 9, 2020 | M.D. Anderson Cancer Center | A study with 0 ACTUAL Enrollment must have Overall Recruitment Status specified as Withdrawn | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | Phase 4 | terminated | Jan 29, 2019 | Indiana University | Study stopped due to staffing issues that impacted ability to recruit. | Enrollment / accrual |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT05641545 | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint… | Phase 1 | terminated | Dec 7, 2022 | SLK Kliniken Heilbronn GmbH | Premature discontinuation due to üoor participant recruitment | Enrollment / accrual |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell… | Phase 2 | terminated | Jun 11, 2018 | Roberto Pili | Funder halted development of compound in this disease | Other (stated, no rule matched) |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT03134027 | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of…(Immune PDX) | — | terminated | Apr 28, 2017 | Duke University | Poor accrual | Enrollment / accrual |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have… | Phase 2 | terminated | May 29, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT03905889 | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Phase 1 | terminated | Apr 5, 2019 | Brown University | Funding withdrawn | Funding |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Dec 1, 2025source: clinicaltrials